A novel bioengineered technique to rapidly and permanently repair cut PNS nerves Our long term objective is to performance-optimize to translate for clinical use our novel and innovative technique to produce rapid and permanent repair of acutely and chronically severed mammalian PNS axons to restore the behavioral functions they mediated prior to severance. We apply a well-specified sequence of bioengineered solutions containing polyethylene glycol (PEG) and various anti-oxidizing or oxidizing agents to rapidly and permanently rejoin (PEG-fuse) completely cut-severed ends of rat sciatic axons as a model in vivo system so that PEG-fused axons are physiologically and morphologically intact through the lesion site and their stimulation restores behavioral functions mediated by intact sciatic nerves. Our physiological and morphological measures of axonal continuity are action potential conduction and intraaxonal dye diffusion across the lesion site and EM and immuno-histochemical analyses.. Our measures of behavioral restoration are Foot Fault Asymmetry test and Sciatic Functional Index. We retard Wallerian degeneration by cooling or cyclosporin A and then repair axons chronically severed for up 10 days by PEG-fusion. We performance optimize tissue (biocompatability) responses of acutely or chronically excised sciatic nerve segments that are used as inter- position autografts or allografts to PEG-fuse repair acutely or chronically cut rat sciatic nerves. Nerve severance is a common traumatic injury to PNS axons in humans. Various procedures currently slightly improve the number and specificity of PNS axons that reestablish connections following severance, but not outgrowth rate (~1mm/day) or time (weeks to years) for PNS axons to re-establish those connections. Target tissues may atrophy before re-innervation can occur. Consequently, target tissues are often non-specifically re-innervated and behavioral recovery is often poor. PEG-fusion dramatically improves the speed and efficacy of behavioral recovery following acute cut- or crush-severance of mammalian PNS axons. We can also retard axonal Wallerian degeneration of severed mammalian axons for up to 10 days to increase the time for successful PEG-fusion for up to 10 days post-severance so that nerve injuries do not have to be immediately treated. Our well-specified sequence of bio-engineered solutions and materials needed for PEG-fusion use only FDA-approved chemicals. Hence, our PEG-fusion technique developed on rat sciatic nerves as a model in vivo system should rapidly translate to clinical procedures. The results of our proposed R-01 have high potential for shifting the current emphasis of current research and clinical practice from devising procedures to enhance the results of slow axonal outgrowth to considering rapid repair by our novel PEG-fusion technique.
Severance of PNS nerves is by far the most common clinical nerve injury and their repair has been a largely-unsolved fundamental problem in neuroscience. Behavioral recovery from such injuries typically takes months to years --- and often the recovery is very poor. We propose to further improve the dramatic success of our novel bio-engineering technique that uses polyethylene glycol and other substances to repair severed peripheral nerve axons in rats as a model system so as to rapidly (within days) and permanently restore many behavioral functions evoked prior to injury. Our procedure uses FDA-approved substances and materials and should be rapidly translatable for clinical use. !
|Riley, D C; Bittner, G D; Mikesh, M et al. (2015) Polyethylene glycol-fused allografts produce rapid behavioral recovery after ablation of sciatic nerve segments. J Neurosci Res 93:572-83|
|Zuzek, Aleksej; Fan, Jerry D; Spaeth, Christopher S et al. (2013) Sealing of transected neurites of rat B104 cells requires a diacylglycerol PKC-dependent pathway and a PKA-dependent pathway. Cell Mol Neurobiol 33:31-46|
|Rodriguez-Feo, Charles L; Sexton, Kevin W; Boyer, Richard B et al. (2013) Blocking the P2X7 receptor improves outcomes after axonal fusion. J Surg Res 184:705-13|